GlassScriptPhysician profile
Amy Morin
NPI 1629617469
$23,906.10
in general payments reported to CMS, 2019-2025
30 companies · $3,809 in 2025
The $3,809 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,861 · 2022: $8,102 · 2023: $7,809 · 2024: $2,325 · 2025: $3,809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,187 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,750 · Education: $6.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,186.62 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,750.00 |
| Education | $6.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $13,904.11 | 2021-2025 | |
| Alkermes, INC. | $1,274.14 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $1,260.73 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,226.43 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,015.42 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $862.52 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Supernus Pharmaceuticals, INC. | $699.89 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $537.00 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Lundbeck LLC | $510.07 | 2021-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $387.70 | 2021-2022 | |
| Corium, LLC | $322.18 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $311.19 | 2021-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $252.47 | 2021-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $233.19 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $223.78 | 2022-2025 | Loreev Xr |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $193.34 | 2022-2023 | Perseris |
| Axsome Therapeutics, INC. | $189.14 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $169.98 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $69.01 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $49.59 | 2023 | Belsomra |
| Harmony Biosciences LLC | $30.95 | 2023-2024 | Wakix |
| Tris Pharma INC | $30.16 | 2023 | Dyanavel Xr |
| Bausch Health US, LLC | $28.20 | 2022 | |
| Alfasigma USA, INC. | $24.43 | 2022 | |
| Allergan, INC. | $21.33 | 2021 | |
| Adlon Therapeutics L.P. | $18.36 | 2021 | |
| Jazz Pharmaceuticals INC. | $17.95 | 2022 | |
| Avanir Pharmaceuticals, INC. | $15.58 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.65 | 2022 | |
| Collegium Pharmaceutical, INC. | $13.61 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Morin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.